VX-371 + Hypertonic Saline + Placebo (0.17% saline) + VX-371 + HS + Ivacaftor
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Ciliary Dyskinesia
Conditions
Primary Ciliary Dyskinesia
Trial Timeline
Aug 1, 2016 → Nov 20, 2018
NCT ID
NCT02871778About VX-371 + Hypertonic Saline + Placebo (0.17% saline) + VX-371 + HS + Ivacaftor
VX-371 + Hypertonic Saline + Placebo (0.17% saline) + VX-371 + HS + Ivacaftor is a phase 2 stage product being developed by Vertex Pharmaceuticals for Primary Ciliary Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02871778. Target conditions include Primary Ciliary Dyskinesia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Ciliary Dyskinesia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02871778 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Ciliary Dyskinesia